Table 5 Baseline characteristics according to allergy status
From: Real-life experience with benralizumab during 6 months
Variables | Non-atopic (n = 28) | Atopic (n = 14) | p |
|---|---|---|---|
Age, years; md (IR) | 56 (20) | 49.5 (15) | 0.153 |
Women, n (%) | 23 (82) | 10 (71) | 0.451 |
BMI, md (IR) | 28.5 (7.5) | 25 (10) | 0.131 |
Age at diagnosis, years; md (IR) | 26.5 (23) | 24.5 (16) | 0.913 |
Corticosteroid-dependent, n (%) | 13 (46) | 4 (28) | 0.331 |
Nasal polyps, n (%) | 5 (18) | 7 (50) | 0.067 |
AERD, n (%) | 3 (11) | 3 (21) | 0.383 |
ACT, md (IR) | 13 (6) | 15 (6) | 0.730 |
ED visits in the previous year; md (IR) | 5 (3) | 3 (3) | 0.062 |
Cycles of OCS in the previous year; md (IR) | 7 (3) | 4.5 (4) | 0.062 |
Oral prednisone (or equivalent) dose, mg/day; md (IR) | 20 (15) | 15 (23) | 0.412 |
Post-BD FEV1, mL; md (IR) | 1520 (910) | 1425 (545) | 0.947 |
Post-BD FEV1, %; md (IR) | 65 (13) | 69.5 (12) | 0.117 |
FeNO, ppb; md (IR) | 68.5 (32.5) | 44.5 (45) | 0.098 |
Blood eosinophil count, cells/ÎĽL; md (IR) | 713 (297) | 695 (235) | 0.743 |
IgE, IU/mL; md (IR) | 53 (106) | 215 (175) | < 0.001 |